©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2024; 30(21): 2748-2750
Published online Jun 7, 2024. doi: 10.3748/wjg.v30.i21.2748
Published online Jun 7, 2024. doi: 10.3748/wjg.v30.i21.2748
Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors
Wei-Nung Liu, Department of Medicine, Tri-Service General Hospital, Taipei 114, Taiwan
Ming-Shen Dai, Division of Hematology/Oncology, Department of Internal Medicine, National Defense Medical Center, Taipei 114, Taiwan
Felicia Lin, Community Care, Minnesota Oncology, Minneapolis, MN 55404, United States
Gen-Min Lin, Department of Medicine, Hualien Armed Forces General Hospital, Hualien City 970, Taiwan
Author contributions: Liu WN wrote the article; Dai MS, Lin F, and Lin GM made critical revisions related to important content of the manuscript; and all authors provided approval of the final version of the article to be published.
Conflict-of-interest statement: All authors declared to have conflict of interest.
Corresponding author: Gen-Min Lin, FACC, FAHA, FESC, MD, PhD, Academic Editor, Academic Fellow, Chief Physician, Department of Medicine, Hualien Armed Forces General Hospital, No. 100 Jinfeng Street, Hualien City 970, Taiwan. farmer507@yahoo.com.tw
Received: March 5, 2024
Revised: April 26, 2024
Accepted: May 11, 2024
Published online: June 7, 2024
Processing time: 90 Days and 6 Hours
Revised: April 26, 2024
Accepted: May 11, 2024
Published online: June 7, 2024
Processing time: 90 Days and 6 Hours
Core Tip
Core Tip: This is an invited editorial for the coming paper “Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis”.